XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics
XOMA Royalty Corporation (NASDAQ: XOMA) and LAVA Therapeutics N.V. (NASDAQ: LVTX) have reached a significant agreement to acquire LAVA. This definitive share purchase agreement outlines that XOMA Royalty will acquire shares of LAVA for an amount ranging from $1.16 to $1.24 per share in cash.
Understanding the Acquisition Agreement
The acquisition includes not just the base price but also a contingent value right (CVR). This CVR enables shareholders of LAVA to receive 75% of net proceeds from LAVA’s partnered assets and other programs. Owen Hughes, CEO of XOMA Royalty, emphasized the potential benefits of this transaction for stakeholders, stating that it could yield substantial returns over time.
Strategic Review Process by LAVA
Steve Hurly, CEO of LAVA, noted that this agreement emerges from a detailed strategic review involving legal and financial advisors. The goal was to maximize shareholder value while ensuring the long-term success of LAVA's operations. The board of directors at LAVA unanimously supports the transaction and recommends that shareholders endorse the Offer.
Transaction Details and Conditions
XOMA Royalty is set to launch a tender offer by the specified date in August, aiming for at least 80% of LAVA’s shares to be tendered. This offer involves several conditions, including shareholder approval and financial requirements. Following the tender process, a corporate reorganization will allow XOMA Royalty to take full ownership of LAVA.
Impact on Clinical Trials
As a part of this acquisition, XOMA Royalty intends to halt the Phase 1 clinical trial of LAVA-1266, which was under investigation for acute myeloid leukemia and related conditions. This strategic decision highlights XOMA Royalty’s focus on optimizing its portfolio to enhance shareholder value.
Advisory Teams Involved
Legal advisors representing XOMA Royalty include well-regarded firms such as Gibson, Dunn & Crutcher LLP. LAVA’s financial guidance is provided by Leerink Partners along with Cooley LLP, ensuring due diligence is maintained throughout the acquisition process.
The Role of XOMA Royalty in Biotech
XOMA Royalty positions itself uniquely in the biotechnology market, acting as a royalty aggregator that supports companies aiming to enhance public health. By acquiring future revenues linked to therapeutic candidates, XOMA provides critical funding that can accelerate drug development without diluting equity for original developers.
About LAVA Therapeutics and Its Innovations
LAVA Therapeutics has pioneered bispecific gamma delta T cell engagers, which hold considerable relevance in the fight against various hematologic cancers. Two of their projects have partnered placements with renowned pharmaceutical leaders, showcasing the company's innovative approach and reliability in advancing therapeutic solutions.
Summary and Looking Ahead
As XOMA Royalty and LAVA Therapeutics move forward with this transaction, the anticipated outcomes reflect a new trajectory in their business strategies. With an eye on future developments, both companies are set to navigate the complexities of biotech with a fresh perspective, staying committed to enhancing the landscape of treatment options for patients.
Frequently Asked Questions
What is the main purpose of the acquisition?
The acquisition aims to expand XOMA Royalty's portfolio by integrating LAVA Therapeutics' innovative biopharmaceutical assets, which are expected to enhance future revenue.
What is the contingent value right associated with the acquisition?
The contingent value right grants LAVA shareholders a share in the net proceeds from certain partnered assets, adding an additional financial incentive beyond the cash offer.
Why was the Phase 1 clinical trial of LAVA-1266 discontinued?
The trial was discontinued as XOMA Royalty focuses on optimizing its assets following the acquisition, shifting resources to support future growth opportunities.
Who were the advisors involved in this transaction?
Advisors included Gibson, Dunn & Crutcher LLP and Loyens & Loeff N.V for XOMA Royalty, and for LAVA, financial advisement was through Leerink Partners and legal support via Cooley LLP.
When is the tender offer expected to commence?
The tender offer is planned to begin by mid-August, allowing shareholders a chance to participate in the acquisition process.
